ROR1 and B-cell chronic lymphocytic leukemia: Taken together, these studies demonstrate that cirmtuzumab can inhibit activation of ROR1-dependent growth/survival/migration-signaling pathways that appear unaffected by treatment with ibrutinib [28], supporting the rationale for clinical evaluation of this antibody alone or in combination with other targeted therapies in patients with CLL.